Abstract:Objective:To investigate the value of postoperative radiotherapy in patients with cT 1-2N 1M 0 breast cancer after neoadjuvant chemotherapy and modified radical mastectomy which postoperative pathology showed that the number of axillary lymph node metastases was 0-3. Methods:One hundred and twenty-eight patients diagnosed with cT 1-2N 1M 0 breast cancer admitted to our hospital from January 1, 2000 to December 31, 2014 were retrospectively reviewed. All patients underwent neoadjuvant chemotherapy and modified radical mastectomy. The number of postoperative axillary lymph node metastases was 0-3. According to whether there was postoperative radiotherapy or not, the whole group of patients was divided into radiotherapy group ( n=87) and non-radiotherapy group ( n=41). In the two groups after operation, there were 43 and 11 patients with 1-3 axillary lymph node metastases (ypN 1), while there were 44 and 30 patients without axillary lymph node metastases (ypN 0) respectively. The 5-year locoregional recurrence-free survival (LRFS) rate, disease-free survival (DFS) rate and overall survival (OS) rate were calculated by Kaplan-Meier method, and the differences were compared by log-rank test. Univariate analysis was performed to analyze the effects of clinical features and treatment on prognosis. Results:The 5-year LRFS rate, DFS rate and OS rate of 128 patients were 91.4%, 82.8% and 93.0% respectively. The 5-year LRFS rates of the patients in the radiotherapy group and the non-radiotherapy group were 94.3% and 85.4% respectively, and the difference was not statistically significant ( χ2=3.055, P=0.080). As well as the 5-year DFS rates were 89.7% and 68.3% respectively, and the difference was statistically significant ( χ2=9.312, P=0.005). The 5-year OS rates were 94.3% and 90.2% respectively, and the difference was not statistically significant ( χ2=0.810, P=0.368). In the subgroup analysis, the 5-year LRFS rates of the patients who had achieved ypN 1 in the radiotherapy group and the non-radiotherapy group were 93.0% and 72.7%, and the 5-year DFS rates were 88.4% and 63.6%, with statistically significant differences ( χ2=4.248, P=0.039; χ2=4.525, P=0.033). The 5-year OS rates were 90.7% and 81.8% respectively, and the difference was not statistically significant ( χ2=0.713, P=0.399). The 5-year LRFS rates of the patients who had achieved ypN 0 in the radiotherapy group and the non-radiotherapy group were 95.5% and 90.0% respectively, with no statistically significant difference ( χ2=0.872, P=0.350). The 5-year DFS rates were 90.9% and 70.0% respectively, with statistically significant difference ( χ2=5.439, P=0.019). The 5-year OS rates were 97.7% and 93.3% respectively, with no statistically significant difference ( χ2=0.876, P=0.349). The univariate analysis indicated that age ( χ2=11.709, P=0.001) and blood vessel invasion ( χ2=7.608, P=0.006) were significant influencing factors for 5-year LRFS rate. Postoperative radiotherapy ( χ2=9.312, P=0.002) was a prognostic factor for 5-year DFS rate. Age ( χ2=6.093, P=0.014) and hormone receptor status ( χ2=3.974, P=0.046) were prognostic factors for OS. Conclusion:For the cT 1-2N 1M 0 breast cancer patients with 1-3 positive axillary lymph nodes after neoadjuvant chemotherapy, postmastectomy radiotherapy has local control benefit, and it can improve DFS. However, the benefit of postoperative radiotherapy needs to be further investigated in patients with pathological negative axillary lymph nodes after neoadjuvant chemotherapy.

Adjuvant Radiation Therapy After Preoperative Chemotherapy

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

The Role of Postmastectomy Radiation Therapy in Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Mastectomy

Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy

Radiotherapy May Play an Important Role in Improving the Efficacy of Breast-Conserving Therapy Compared with Mastectomy in Patients with T1-2N1M0 Breast Cancer

Outcome of Postmastectomy Radiotherapy after Primary Systemic Treatment in Patients with Clinical T1-2N1 Breast Cancer.

Disscussion and analysis of the effect of adjuvant radiotherapy after neoadjuvant chemotherapy for stage T1-2N1M0 breast cancer

The Impact of Disparate Subtypes of Breast Cancer and Response to Postoperative Radiation Therapy in Neoadjuvant Setting

Determinants of pathological complete response and tumor regression in high-risk breast cancer treated with neoadjuvant radiotherapy and chemotherapy.

Analysis of Patients Unable to Undergo Adjuvant Chemotherapy after Surgery in Stage IIIA/B Non-Small Cell Lung Cancer: Will They Benefit from Mediastinal Radiotherapy?

Neoadjuvant Radiotherapy of Early-Stage and Locally Advanced Breast Cancer: Review of the Literature

Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer with Modern Systemic Therapy

Survival Analysis of Postmastectomy Radiotherapy for Breast Cancer Staged in Ct 1-2N 1M 0 after Neoadjuvant Chemotherapy with 0-3 Metastatic Lymph Nodes

The addition of radiotherapy to breast-conserving surgery improves survival for elderly patients with early breast cancer

Abstract P1-14-18: Postmastectomy Radiotherapy Improves the Outcomes of Stage III Breast Cancer Patients with Negative Lymph Nodes after Neoadjuvant Chemotherapy

Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer

Current and future role of neoadjuvant therapy for breast cancer

Value of postmastectomy radiotherapy in locally advanced breast cancer patients treated with neoadjuvant chemotherapy and modified radical mastectomy

The Role of Postmastectomy Radiation Therapy for Clinical Stage II-III Breast Cancer Patients with Pathological Complete Remission of Axillary Lymph Nodes after Neoadjuvant Chemotherapy

Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT1-2N+ Breast Cancer Patients: A Single Center Experience and Review of Current Literature

Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy